AbbVie has announced that it will be acquiring Aliada Therapeutics for $1.4bn, marking a notable boost to its neuroscience ...

Around 86% of clinical trials do not meet patient recruitment goals, ultimately failing to improve patient outcomes and ...

Knowing this, it amazes me how many pharmaceutical organisations of all sizes are missing the mark on key areas of launch ...

Generative AI platforms are revolutionizing drug discovery, driving significant biopharma dealmaking by enabling the design ...

Every year, the medical community recognizes the month of November as Clostridioides difficile (C. diff) Awareness month. C.

Johnson & Johnson (J&J) has shared positive results from a late-stage study of its dual-acting IL-23 inhibitor Tremfya ...

Pharma companion apps are transforming healthcare by offering support beyond traditional treatments, enhancing patient ...

Novartis’ Kisqali (ribociclib) has been recommended by the European Medicines Agency’s human medicines committee to reduce the risk of recurrence in early breast cancer patients. The Committee for ...

AstraZeneca’s (AZ) Voydeya (danicopan) has been recommended by the National Institute for Health and Care Excellence (NICE) as an add-on therapy for adults with the rare blood disorder paroxysmal ...

Merck & Co’s – known as MSD outside the US and Canada – Keytruda (pembrolizumab) has been recommended by the National Institute of Health and Care Excellence (NICE) to treat resectable non-small cell ...

The health technology assessment agency said that more evidence is needed on the clinical and cost-effectiveness of the drug Eli Lilly’s amyloid plaque-targeting Alzheimer’s disease (AD) drug has been ...

Merck & Co – known as MSD outside the US and Canada – has acquired Yale University oncology spinout Modifi Biosciences in a deal worth $1.3bn. The agreement gives Merck access to preclinical compounds ...